electroCore Announces Publication in PharmacoEconomics Reiterating Economic Benefits of gammaCore for Cluster Headache Outlined by The National Institute for Health and Care Excellence (NICE) Medical Technologies Guidance
04 Agosto 2021 - 9:00AM
electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic
medicine company (the Company), today announced the release of an
article entitled “gammaCore for Cluster Headaches: A NICE Medical
Technologies Guidance” in the journal PharmacoEconomics
highlighting the cost impact of gammaCore’s non-invasive vagus
nerve stimulation therapy platform for patients with cluster
headaches.
The paper is part of a series that provides insight into the
development of UK National Institute for Health and Care Excellence
(NICE) medical technologies guidance for new or innovative medical
devices or diagnostics. The aim of the guidance is to support the
adoption of clinically effective and cost-saving technologies in
the UK National Health Service. The paper validated that gammaCore
both reduces the frequency and severity of cluster headaches when
used with standard of care and provides a £450 per patient savings
in the first year of therapy versus standard of care
alone.“PharmacoEconomics reiterating the evidence supporting
gammaCore’s effectiveness and economic benefit provides further
support that gammaCore can play an important role in providing
value-based therapy” commented Iain Strickland, VP Global Sales and
Strategy of electroCore. “We look forward to the growth of our UK
business as we continue to educate prescribers and payers on both
the NICE medical technologies guidance and the MedTech Funding
Mandate policy throughout the year. “
The article can be accessed at:
https://link.springer.com/article/10.1007/s41669-021-00276-5
About gammaCoreTMgammaCoreTM
(nVNS) is the first non-invasive, hand-held medical therapy applied
at the neck as an adjunctive therapy to treat migraine and cluster
headache through the utilization of a mild electrical stimulation
to the vagus nerve that passes through the skin. Designed as a
portable, easy-to-use technology, gammaCore can be
self-administered by patients, as needed, without the potential
side effects associated with commonly prescribed drugs. When placed
on a patient’s neck over the vagus nerve, gammaCore stimulates the
nerve’s afferent fibers, which may lead to a reduction of pain in
patients.
gammaCore (nVNS) is FDA cleared in the United States for
adjunctive use for the preventive treatment of cluster headache in
adult patients, the acute treatment of pain associated with
episodic cluster headache in adult patients, and the acute and
preventive treatment of migraine in adolescent (ages 12 and older)
and adult patients. gammaCore is CE-marked in the European Union
for the acute and/or prophylactic treatment of primary headache
(Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and
Hemicrania Continua) and Medication Overuse Headache in adults.
gammaCore is contraindicated for patients if they:
- Have an active implantable medical device, such as a pacemaker,
hearing aid implant, or any implanted electronic device
- Have a metallic device, such as a stent, bone plate, or bone
screw, implanted at or near the neck
- Are using another device at the same time (e.g., TENS Unit,
muscle stimulator) or any portable electronic device (e.g., mobile
phone)
Safety and efficacy of gammaCore have not been evaluated in the
following patients:
- Patients diagnosed with narrowing of the arteries (carotid
atherosclerosis)
- Patients who have had surgery to cut the vagus nerve in the
neck (cervical vagotomy)
- Pediatric patients (less than 12 years)
- Pregnant women
- Patients with clinically significant hypertension, hypotension,
bradycardia, or tachycardia
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include, but are not limited to,
statements about electroCore’s expectations for revenue and cash
used in operations during the third quarter of 2021, its
expectations for future performance, as well as electroCore's
business prospects and clinical and product development plans for
2021 and beyond, its pipeline or potential markets for its
technologies, additional indications for gammaCore, the timing,
outcome and impact of regulatory, clinical and commercial
developments, further international expansion, and statements about
anticipated distribution arrangements, government and payor funding
arrangements (including those relating to the NICE Medical
Technologies Guidance or MedTech Funding Mandate) and other
statements that are not historical in nature, particularly those
that utilize terminology such as "anticipates," "will," "expects,"
"believes," "intends," other words of similar meaning, derivations
of such words and the use of future dates. Actual results could
differ from those projected in any forward-looking statements due
to numerous factors. Such factors include, among others, the
ability to raise the additional funding needed to continue to
pursue electroCore’s business and product development plans, the
inherent uncertainties associated with developing new products or
technologies, the ability to commercialize gammaCore™, competition
in the industry in which electroCore operates and overall market
conditions. Any forward-looking statements are made as of the date
of this press release, and electroCore assumes no obligation to
update the forward-looking statements or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should consult all of the information set forth herein and should
also refer to the risk factor disclosure set forth in the reports
and other documents electroCore files with the SEC available at
www.sec.gov.
Investors:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital
or
Media Contact:
Jackie Dorsky
electroCore
908-313-6331
Jackie.dorsky@electrocore.com
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
electroCore (NASDAQ:ECOR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024